Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Tumor-Agnostic 1

Conditions

Leiomyosarcoma 2Neoplasms 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × PTC596 × Clear all
NCT05269355 2025-06-13

SUNRISELMS

PTC Therapeutics

Phase 2/3 Terminated
359 enrolled 15 charts
Sarcoma

Leiomyosarcoma

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

NCT02404480 2017-12-08

PTC596 in Patients With Advanced Solid Tumors

PTC Therapeutics

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡